meplazumab

Home
Ligands
meplazumab

GtoPdb Ligand ID: 11026

Synonyms: HP6H8 | Ketantin®

Comment: Meplazumab is a humanized IgG2 monoclonal antibody that targets CD147 (basigin). It is being developed by Jiangsu Pacific Meinuoke Bio Pharmaceutical.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.

SARS-CoV-2 and COVID-19: SARS-CoV-2 may utilise CD147 as an additional entry receptor to infect host cells [2]. Meplazumab can block this interaction between CD147 and SARS-CoV-2 spike protein.

Guide to Malaria Pharmacology Comments
Meplazumab has progressed to clinical evaluation as a new asexual blood stage macromolecular antibody therapy, that could mediate both treatment and prophylaxis of P. falciparum malaria. This follows preclinical studies indicating that meplazumab is well tolerated and has excellent efficacy in the treatment and prevention of severe malaria in humanized mice [3-4].

Guide to Malaria Pharmacology Comments

Meplazumab has progressed to clinical evaluation as a new asexual blood stage macromolecular antibody therapy, that could mediate both treatment and prophylaxis of P. falciparum malaria. This follows preclinical studies indicating that meplazumab is well tolerated and has excellent efficacy in the treatment and prevention of severe malaria in humanized mice [3-4].